NCT05438290View on ClinicalTrials.gov

DPCP to Treat Cutaneous Neurofibromas Associated With NF1

PHASE1CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

May 17, 2023

Study Completion Date

May 17, 2023

Conditions

Cutaneous Neurofibroma

Interventions

DRUG

DPCP

topical immunomodulator

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors

lead

Nicholas Gulati

OTHER